Feasibility of the GenoType MTBDR sl Assay for Fluoroquinolone, Amikacin-Capreomycin, and Ethambutol Resistance Testing of Mycobacterium tuberculosis Strains and Clinical Specimens
- 1 June 2009
- journal article
- research article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 47 (6) , 1767-1772
- https://doi.org/10.1128/jcm.00081-09
Abstract
The new GenoType Mycobacterium tuberculosis drug resistance second line (MTBDR sl ) assay (Hain Lifescience, Nehren, Germany) was tested on 106 clinical isolates and directly on 64 sputum specimens for the ability to detect resistance to fluoroquinolones, injectable drugs (amikacin or capreomycin), and ethambutol in Mycobacterium tuberculosis strains. A total of 63 strains harboring fluoroquinolone, amikacin/capreomycin, or ethambutol resistance and 43 fully susceptible strains were comparatively analyzed with the new MTBDR sl assay, by DNA sequencing, and by conventional drug susceptibility testing in liquid and solid media. No discrepancies were obtained in comparison with the DNA sequencing results. Fluoroquinolone resistance was detected in 29 (90.6%) of 32, amikacin/capreomycin resistance was detected in 39/39 (84.8%/86.7%) of 46/45, and ethambutol resistance was detected in 36 (69.2%) of 52 resistant strains. A total of 64 sputum specimens (42 smear positive, 12 scanty, and 10 smear negative) were tested with the new MTBDR sl assay, and the results were compared with those of conventional drug susceptibility testing. Fluoroquinolone resistance was detected in 8 (88.9%) of 9, amikacin/capreomycin resistance was detected in 6/7 (75.0%/87.5%) of 8, and ethambutol resistance was detected in 10 (38.5%) of 26 resistant strains. No mutation was detected in susceptible strains. The new GenoType MTBDR sl assay represents a reliable tool for the detection of fluoroquinolone and amikacin/capreomycin resistance and to a lesser extent also ethambutol resistance. In combination with a molecular test for detection of rifampin and isoniazid resistance, the potential for the detection of extensively resistant tuberculosis within 1 to 2 days can be postulated.Keywords
This publication has 23 references indexed in Scilit:
- Molecular Characterization of Ofloxacin-ResistantMycobacterium tuberculosisStrains from RussiaAntimicrobial Agents and Chemotherapy, 2008
- Transfer of embB Codon 306 Mutations into Clinical Mycobacterium tuberculosis Strains Alters Susceptibility to Ethambutol, Isoniazid, and RifampinAntimicrobial Agents and Chemotherapy, 2008
- Detection of mutations in Mycobacterium tuberculosis genome determining resistance to fluoroquinolones by hybridization on biological microchipsBulletin of Experimental Biology and Medicine, 2008
- Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysisYearbook of Pulmonary Disease, 2008
- Worldwide Emergence of Extensively Drug-resistant TuberculosisEmerging Infectious Diseases, 2007
- Detection of Multidrug Resistance in Mycobacterium tuberculosisJournal of Clinical Microbiology, 2007
- Use of Smear-Positive Samples To Assess the PCR-Based Genotype MTBDR Assay for Rapid, Direct Detection of the Mycobacterium tuberculosis Complex as Well as Its Resistance to Isoniazid and RifampinJournal of Clinical Microbiology, 2006
- Direct Detection of Mycobacterium tuberculosis Complex DNA and Rifampin Resistance in Clinical Specimens from Tuberculosis Patients by Line Probe AssayJournal of Clinical Microbiology, 2006
- Rapid Genotypic Detection of Rifampin- and Isoniazid-Resistant Mycobacterium tuberculosis Directly in Clinical SpecimensJournal of Clinical Microbiology, 2006
- Significance of Mutations in embB Codon 306 for Prediction of Ethambutol Resistance in Clinical Mycobacterium tuberculosis IsolatesAntimicrobial Agents and Chemotherapy, 2006